VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 1, 2008) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) (“EnWave” or the “Company”) is pleased to report that it has received positive results from the Company’s first room temperature shelf-life study of dehydrated rotavirus vaccine conducted by its collaboration partner Aridis Pharmaceuticals, LLC (“Aridis”) of San Jose, California. The Company believes it is now one step closer to developing a new industry standard technology for dehydrating vaccines and antibodies.
